New Graves' disease treatment begins first human testing
NCT ID NCT06980649
Summary
This early study is testing whether a new drug called BHV-1300 is safe for people with Graves' disease, an autoimmune condition affecting the thyroid. Researchers will enroll 15 participants to monitor for side effects and check if the treatment affects specific markers of the disease in the blood. The main goal is to understand safety over a 12-week treatment period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAVES' DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site-001
RECRUITINGKotara, 2289, Australia
-
Site-002
RECRUITINGTorquay, 3228, Australia
-
Site-003
RECRUITINGMelbourne, 3128, Australia
-
Site-004
RECRUITINGFitzroy, 3065, Australia
-
Site-006
RECRUITINGSt Leonards, 2065, Australia
-
Site-008
RECRUITINGParkville, 3050, Australia
-
Site-100
RECRUITINGMiami, Florida, 33126, United States
-
Site-101
RECRUITINGHouston, Texas, 77095, United States
-
Site-103
RECRUITINGSouth Gate, California, 90280, United States
-
Site-104
RECRUITINGColumbus, Georgia, 31904, United States
-
Site-105
RECRUITINGShavano Park, Texas, 78231, United States
-
Site-106
RECRUITINGHouston, Texas, 77054, United States
Conditions
Explore the condition pages connected to this study.